Evidence map›Paper›PMID 34671774›Full record

ArticlemedRxiv : the preprint server for health sciences2021

A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients.

Andrew H Karaba, Xianming Zhu, Tao Liang, Kristy H Wang, Alex G Rittenhouse, Olivia Akinde, Yolanda Eby, Jessica E Ruff, Joel N Blankson, Aura T Abedon and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 33 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Andrew H KarabaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Xianming ZhuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Tao LiangDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Kristy H WangDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Alex G RittenhouseDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Olivia AkindeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Yolanda EbyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jessica E RuffDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Joel N BlanksonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Aura T AbedonDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jennifer L AlejoDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Andrea L CoxDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Justin R BaileyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Elizabeth A ThompsonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Sabra L KleinDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Daniel S WarrenDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jacqueline M Garonzik-WangDepartment of Surgery, University of Wisconsin School of Medicine and Health, Madison, WI 53792, USA.
Brian J BoyarskyDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ioannis SitarasW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
Andrew PekoszDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Dorry L SegevDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Aaron A R TobianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
William A WerbelDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Johns Hopkins University · USBloomberg (United States) · USUniversity of Wisconsin–Madison · US

Funding

Clinical and Laboratory Research Training for Gastrointestinal SurgeonsT32DK007713 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI DAVID J HACKAM · 1996 to 2026
$5.2M
Unlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3M
Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2K08AI156021 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARABA, ANDREW HOOVER · 2021 to 2025
$994k
Patient Oriented Research in Solid Organ TransplantationK24AI144954 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SEGEV, DORRY L. · 2020 to 2024
$956k
The Landscape of Serious Infections following Kidney Transplantation in People Living with HIVK23AI157893 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WERBEL, WILLIAM · 2021 to 2025
$847k
Aggressive Center Report Cards to Safely Increase Transplantation of Suboptimal KidneysK23DK115908 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI GARONZIK WANG, JACQUELINE M · 2018 to 2021
$516k
Aggressive Organ Procurement Organization Report Cards to Safely Increase Kidney TransplantationF32DK124941 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI BOYARSKY, BRIAN · 2020 to 2020
$81k
NIAID NIH HHS HHSN272201400007CNIAID NIH HHS K08 AI156021NIAID NIH HHS K23 AI157893NIAID NIH HHS K24 AI144954NIAID NIH HHS R01 AI120938NIDDK NIH HHS F32 DK124941NIDDK NIH HHS K23 DK115908NIDDK NIH HHS T32 DK007713
6 · The paper itself

Abstract

Vaccine-induced SARS-CoV-2 antibody responses are attenuated in solid organ transplant recipients (SOTRs) and breakthrough infections are more common. Additional SARS-CoV-2 vaccine doses increase anti-spike IgG in some SOTRs, but it is uncertain whether neutralization of variants of concern (VOCs) is enhanced. We tested 47 SOTRs for clinical and research anti-spike IgG, pseudoneutralization (ACE2 blocking), and live-virus neutralization (nAb) against VOCs before and after a third SARS-CoV-2 vaccine dose (70% mRNA, 30% Ad26.COV2.S) with comparison to 15 healthy controls after two mRNA vaccine doses. We used correlation analysis to compare anti-spike IgG assays and focused on thresholds associated with neutralizing activity. A third SARS-CoV-2 vaccine dose increased median anti-spike (1.6-fold) and receptor-binding domain (1.5-fold) IgG, as well as pseudoneutralization against VOCs (2.5-fold versus Delta). However, IgG and neutralization activity were significantly lower than healthy controls (p<0.001); 32% of SOTRs had zero detectable nAb against Delta after third vaccination. Correlation with nAb was seen at anti-spike IgG >4 AU on the clinical assay and >10^4 AU on the research assay. These findings highlight benefits of a third vaccine dose for some SOTRs and the need for alternative strategies to improve protection in a significant subset of this population.

Identifiers

PMID34671774
PMCPMC8528082
OpenAlexW3194679520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.